Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06149221 · ClinicalTrials.gov registry record · NA
Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss
A NA study of Androgenetic Alopecia, sponsored by Dr. Peter C. Friedman.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT06149221: Completed NA study of Androgenetic Alopecia, sponsored by Dr. Peter C. Friedman.
NCT06149221 is a NA study of Androgenetic Alopecia that has completed, run by Dr. Peter C. Friedman. The registered enrollment target is 19 participants, below the 164-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06149221, a NA study of Androgenetic Alopecia, has completed, sponsored by Dr. Peter C. Friedman.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
In-office applied non-thermal atmospheric pressure plasma treatment on NS pretreated scalp
Primary Outcome
Presence of hair growth as measured using the HairMetrix device
Conditions Studied
Interventions
- DEVICE NTAP
Study Locations (1)
New York
- The Skin Center Dermatology Group - New City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2024-04-12 |
| Phase | NA |
What the finished NCT06149221 record still lists
NCT06149221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 164-participant average among 16 other Androgenetic Alopecia trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Androgenetic Alopecia appearing as the primary indexed condition, and to 1 intervention - of which NTAP is the first listed.
NCT06149221 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06149221 about?
NCT06149221 is a clinical study titled "Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss". In-office applied non-thermal atmospheric pressure plasma treatment on NS pretreated scalp
What is the current status of trial NCT06149221?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2023-09-01. Estimated completion is 2024-04-12.
What conditions does trial NCT06149221 study?
This clinical trial studies the following conditions: Androgenetic Alopecia.
What interventions are being tested in trial NCT06149221?
The interventions under investigation include: NTAP (DEVICE).
Who is sponsoring clinical trial NCT06149221?
This trial is sponsored by Dr. Peter C. Friedman, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06149221 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Androgenetic Alopecia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06149221's enrollment target sits among peer trials
19 16th of 16 higher than 1 of 16 other Androgenetic Alopecia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Androgenetic Alopecia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sham LaserCap vs. LaserCap SD vs. LaserCap HD+
RECRUITING · NA
-
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
RECRUITING · NA
-
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
COMPLETED · NA
-
Computer-Assisted Versus Manual Hair Harvest Comparative Study
COMPLETED · NA
-
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss
COMPLETED · NA
-
A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI